Epix to retain Nasdaq listing

By AuntMinnie.com staff writers

February 9, 2009 -- MRI contrast developer Epix Pharmaceuticals of Lexington, MA, said that its request for continued listing on the Nasdaq Global Market has been granted.

The ruling by the Nasdaq Listing Qualifications Panel is subject to the condition that Epix file a current report on Form 8-K with the U.S. Securities and Exchange Commission (SEC) by May 11, attesting to its compliance with SEC requirements of maintaining shareholders' equity of at least $10 million or a minimum market value of listed securities of $50 million.